Please assess the completion status of the following clinical trial:

Trial Title: Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Age \> 18 years~Relapsed or progressive multiple myeloma (MM) (Progressive Disease), defined as a 25% increase from the lowest response value in ANY of the following:~Serum M-protein (absolute increase ≥0.5 g/dL)~Urine M-protein (absolute increase of ≥200 mg/24 hours)~Bone marrow plasma cell percentage (≥ 10% absolute increase) in absence of measurable M-protein~Difference in kappa \& lambda free light chain levels (ratio must be abnormal; absolute change must be \>10 mg/dL)~Patients are also considered to have progressive disease when:~New bone or soft tissue lesions (e.g. plasmacytomas) are identified; or~There is an unequivocal increase in the size of previously existing lesions; or~The development of an otherwise unexplained serum calcium \>11.5 mg/dL~Have received 1, but no more than 4 prior treatment regimens or lines of therapy for MM (Induction therapy followed by stem cell transplant \& consolidation/maintenance therapy will be considered as one line of therapy)~ECOG Performance status 0 - 2~Life expectancy of at least 12 weeks~Evaluable MM with, at least one of the following, assessed within 21 days prior to randomization:~Serum M-protein ≥ 0.5 g/dL, or Urine M-protein ≥ 200 mg/24 hour, or~In absence of detectable serum or urine M-protein, serum FLC (SFLC) \> 100 mg/L (involved light chain) and/or an abnormal kappa/lamda ratio (\>4:1 or \<2:1), or~Monoclonal plasma cells in a bone marrow biopsy/aspirate of \>5%~Adequate organ and marrow function as defined below:~* Leukocytes ≥ 2,500/mcL~* Absolute neutrophil count ≥ 1,500/mcL~* Platelets ≥ 100,000/mcL~* Total bilirubin \< 2 X ULN~* AST(SGOT)/ALT(SPGT) ≤ 2.5 X ULN~* Creatinine \< 1.5 X ULN~Contraception Women of child-bearing potential and men must agree to use adequate contraception prior to study entry, for duration of study, and for 90 days after completion of therapy.~A female of child-bearing potential is considered to be any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:~* No hysterectomy or bilateral oophorectomy; or~* Not naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).~Male patients must use an effective barrier method of contraception during study and for 3 months following the last dose if sexually active with a female of child-bearing potential.~No prior therapy with pomalidomide or everolimus.~Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~Have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.~Receiving any other investigational agents. Minimum 4 week washout period is required.~History of allergic reactions attributed to compounds of similar chemical or biologic composition to pomalidomide, everolimus, or other agents used in the study.~Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~Pregnant or nursing (due to the rick for congenital abnormalities and the potential of this regimen to harm nursing infants).~Glucocorticoid therapy (prednisone \> 30 mg/day or equivalent) within 14 days prior to randomization.~POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).~Plasma cell leukemia or circulating plasma cells ≥ 2 × 10\^9/L.~Waldenstrom's Macroglobulinemia.~Patients with known amyloidosis.~Focal radiation therapy within 7 days prior to randomization. Radiation therapy to an extended field involving a significant volume of bone marrow within 21 days prior to randomization (i.e., prior radiation must have been to less than 30% of the bone marrow).~Immunotherapy within 21 days prior to randomization.~Myelodysplastic syndrome~Major surgery (excluding kyphoplasty) within 28 days~Known cirrhosis.~Significant neuropathy (Grades 3 to 4, or Grade 2 with pain) within 14 days~Ongoing graft-vs-host disease.~Using CYP3A4 inhibitors such as Ketoconazole, Ritonavir, Itraconazole, Erythromycin, Clarithromycin, Nelfinavir, Fluconazole, Amiodarone, Cyclosporine, Diltiazem, nefazadone,fluvoxamine, verapamil, chloramphenicol, Indinavir or saquinavir within 7 days of treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combination therapy (Type: EXPERIMENTAL): Pomalidomide: 1 tablet orally, daily for 21 days of a 28 day cycle (dose per cohort) Everolimus: 1 tablet orally for 21 days of a 28 day cycle (dose as per cohort) Dexamethasone 40 mg (20 mg \>75yrs) orally, days 1, 8,15, 22 of a 28 day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).